Patented Medicine Prices Review Board will hear evidence regarding alleged breach of reporting requirements for acne drugs
The public hearing is scheduled to take place from 10:00 a.m. to 4:00 p.m. (EST) from September 26 to September 27, 2016 at the following location:
Patented Medicine Prices Review Board
Hearing Room #2, 18th floor
333 Laurier Avenue West
Ottawa, Ontario K1P 1C1
The purpose of the hearing is to receive evidence and argument of Board Staff and Galderma Canada Inc. regarding allegations that Galderma Canada Inc. is in breach of its reporting requirements.
- The Patented Medicine Prices Review Board is an independent quasi-judicial body that protects the interests of Canadian consumers by ensuring the prices of patented medicines sold in Canada are not excessive.
- Patentees must file price and sales information with the Patented Medicine Prices Review Board at introduction, and twice a year afterward, for each strength of each dosage form of each patented medicine sold in Canada.
- Board Staff review the prices patentees charge for each individual patented drug product sold in Canadian markets on an ongoing basis to ensure they are not excessive.
- If the Hearing Panel of the Board finds a patentee to be in breach of its reporting requirements, it may order the patentee to provide Board Staff with the required pricing and sales information.